Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents Over Three Decades, 1995-2017: Cross-Sectional Analysis

Audrey D. Zhang, Jeremy Puthumana, Nicholas S. Downing, Nilay D. Shah, Harlan Krumholz, Joseph S. Ross
doi: https://doi.org/10.1101/19007047

Article Information

doi 
https://doi.org/10.1101/19007047
History 
  • September 23, 2019.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Audrey D. Zhang1 (audrey.d.zhang{at}gmail.com),
  2. Jeremy Puthumana2 (jeremy.puthumana{at}yale.edu),
  3. Nicholas S. Downing3 (nsdowning{at}gmail.com),
  4. Nilay D. Shah4 (shah.nilay{at}mayo.edu),
  5. Harlan Krumholz5 (harlan.krumholz{at}yale.edu) and
  6. Joseph S. Ross5,6 (joseph.ross{at}yale.edu)
  1. 1 New York University School of Medicine;
  2. 2 Yale School of Medicine;
  3. 3 Bain Capital;
  4. 4 Mayo Clinic;
  5. 5 Yale University
  1. ↵* Corresponding author; email: joseph.ross{at}yale.edu
Back to top
Posted September 23, 2019.
Download PDF

Supplementary Material

Data/Code
Email
Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents Over Three Decades, 1995-2017: Cross-Sectional Analysis
Audrey D. Zhang, Jeremy Puthumana, Nicholas S. Downing, Nilay D. Shah, Harlan Krumholz, Joseph S. Ross
medRxiv 19007047; doi: https://doi.org/10.1101/19007047
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools

Subject Area